ONCOTARTIS

OncoTartis is exploring a proprietary drug discovery approach called "TARTIS" (TARTIS = TAR geting TIS sue). TARTIS is designed to develop small molecules for treatment of malignancies originating from specific tissues that are either non-essential for the general viability of mammalian organism (i.e., gender-associated tissues or melanocytes) or can be effectively replaced (hematopoietic system). TARTIS technology involves screening of chemical and/or shRNA libraries for identification of small molecules and shRNAs corresponding to specific genes, which are capable of selective killing of cells representing the tissue of choice... OncoTartis, Inc. is a private biotechnology company established in 2011. Company's founding IP came from Prof. Andrei Gudkov's laboratory at Roswell Park Cancer Institute (Buffalo, NY). OncoTartis develops a novel category of anti-cancer drugs directed against tissue-specific targets for a subset of cancers (breast, prostate, ovarian, melanoma and..

Also known as: OncoTartis, Inc.

Primary location: Buffalo United States